Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $166.00 target price on the biotechnology company’s stock. Needham & Company LLC’s price target would suggest a potential upside of 24.20% from the company’s current price.

SRPT has been the topic of several other research reports. UBS Group boosted their price target on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Royal Bank of Canada boosted their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Mizuho boosted their price target on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Finally, Evercore ISI boosted their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $160.60.

Sarepta Therapeutics Trading Up 2.3 %

Shares of NASDAQ:SRPT traded up $3.03 during midday trading on Thursday, hitting $133.66. 1,196,284 shares of the stock traded hands, compared to its average volume of 876,130. The stock has a market capitalization of $12.63 billion, a PE ratio of 1,215.09 and a beta of 0.95. The business’s 50 day moving average is $125.63 and its two-hundred day moving average is $110.81. The company has a quick ratio of 3.45, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.44) earnings per share. As a group, research analysts forecast that Sarepta Therapeutics will post 2.14 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Bilal Arif sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now owns 7,516 shares in the company, valued at approximately $923,941.88. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,096 shares of company stock worth $2,739,419. Corporate insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SRPT. DMC Group LLC lifted its position in Sarepta Therapeutics by 2.9% during the third quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock valued at $400,000 after purchasing an additional 93 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Sarepta Therapeutics by 5.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 95,865 shares of the biotechnology company’s stock valued at $11,621,000 after purchasing an additional 4,763 shares during the period. TD Asset Management Inc lifted its position in Sarepta Therapeutics by 377.7% during the third quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock valued at $24,805,000 after purchasing an additional 161,788 shares during the period. Eagle Health Investments LP raised its position in Sarepta Therapeutics by 79.0% in the third quarter. Eagle Health Investments LP now owns 174,212 shares of the biotechnology company’s stock worth $21,118,000 after acquiring an additional 76,872 shares during the period. Finally, Hudson Capital Management LLC bought a new position in Sarepta Therapeutics in the third quarter worth approximately $206,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.